On November 5, 2020, my country's first centralized procurement of coronary stents.

Ten varieties won the bid, and the price dropped from an average price of 13,000 yuan to about 700 yuan.

  On January 1 this year, the national centralized collection of coronary stents was implemented in 18 provinces, autonomous regions and municipalities including Beijing, Tianjin, Liaoning, Hunan, etc. This means that patients in these places can use reduced-price coronary stents.

  In Huzhou, Zhejiang, 81-year-old Lu Meijiang came to Huzhou Central Hospital for treatment with angina.

After examination, the doctor found that Lu Meijiang’s coronary arteries were severely stenosis, with more than 95% of the two blood vessels blocked, which was very prone to acute myocardial infarction and life-threatening.

In the early morning of the 1st, the hospital adopted catheter intervention surgery and implanted 2 coronary stents for the patient.

Lu Meijiang’s daughter Lu Jiandi:

These two stents were cheaper by more than 20,000 yuan. Later, two balloons were installed, which was more than 8,000 yuan cheaper. Let's calculate that it will cost more than 30,000 yuan (cheap).

Yu Haifeng, chief physician of the Department of Cardiology, Huzhou Central Hospital: After the

implementation of the new price policy, the quality of the stents and balloon materials for the new bidding will be the same as before. It is not said that the price is much cheaper and some different things will be introduced. It is possible that the country has quality control and indicators, and things are the same.

  In Xiangtan, Hunan, 76-year-old Xiang Donglin suddenly suffered chest pain and fell to the ground on New Year’s Eve. He was rushed to Xiangtan First People’s Hospital. He was diagnosed as "acute myocardial infarction" by the chest pain center. On January 1, 2021, medical affairs The staff performed coronary stent surgery for Xiang Donglin.

After the operation, when they learned that a stent cost only 798 yuan, the elderly family was very excited.

Xiang Donglin's daughter Zhang Hecui:

I am very grateful for the country's care and love for our peasants. I am really happy to hear this news, because it is really not easy for us to work outside to earn a penny.

  In order to ensure that patients can use the selected products on January 1, 2021, Xiangtan First People's Hospital has arranged the procurement of the selected stent in place.

Wu Yongjun, deputy dean of Xiangtan First People's Hospital:

Our hospital also reserves more than 20% of our annual surgical volume and stent usage in accordance with document requirements. This can guarantee our patients and existing patients for at least one month. The supply can be guaranteed, the price is significantly lower than before, and the quality (national procurement) is also very guaranteed.

High-volume market concentrates on recruiting to promote bracket price reduction

  The national centralized collection of coronary stents dropped by an average of 93%, and the median price was around 700 yuan.

Factors such as centralized bidding and procurement and reduction of intermediate circulation links have contributed to substantial price cuts.

  At present, from the perspective of market competition, the total market share of the three domestic coronary stent companies has reached 67%. Of the 10 varieties selected this time, 7 are domestically produced, and the quality of domestic coronary stents has been marketed and clinically used. Double verification, companies comply with national reform measures, keep their share through price cuts, and further increase market share.

Chen Jinfu, Deputy Director of the National Medical Security Administration:

Then the main purpose of centralized bidding and procurement should be to eliminate gold sales here. Through this kind of market exchange, volume and price linkage, and the integration of recruitment and procurement to promote the new field of recruitment and procurement. Mechanism reconstruction.

  The gray price moisture of coronary stents is squeezed out through the reasonable mechanism of price found in the market. The most important thing is to squeeze the moisture including circulation, rather than sacrificing production process, standard technology and quality.

A certain medical device company Yu Suhua:

We used to have hundreds of distributors, first-level, second-level, and more agents at all levels in the country. Not us, the entire industry is like this, and it has been developing like this. , But after this centralized procurement, in the final analysis, it is to make the industry more transparent, with fewer intermediate links. I believe that after this centralized procurement, most of the companies are the same as us, basically manufacturers directly to the hospital.

  As of December 30, 2020, the local inventory of selected products in the first batch of 18 provinces, municipalities, and municipalities has reached an average of 33% of the annual contracted purchase volume, reducing intermediate circulation links, promising companies have predictable purchases and quick return The payment mechanism, etc., are all the reasons for companies to cut prices.

Treatment of acute myocardial infarction in China is seriously under-treated

  Data show that the number of interventional cases of coronary heart disease in my country exceeds 1 million, and the use of coronary stents exceeds 1.6 million.

  Experts say that the treatment of acute myocardial infarction in my country is still seriously insufficient.

  Coronary stents, also known as heart stents, are commonly used medical devices in percutaneous coronary intervention (PCI).

Currently, my country's demand for coronary stents is in a rapid release stage.

Data show that from 2015 to 2019, the number of PCI surgeries in my country increased from 568,000 to 1.098 million, a compound annual growth rate of 17.9%.

It is understood that China has an average of 542 patients undergoing coronary interventional treatment for every 1 million people, while there are more than 2,000 cases per 1 million people in Japan and 3,000 cases in the United States during the same period.

It can be seen that the number of coronary interventions per capita in China is still at a low level compared with developed countries.

Huo Yong, head of the cardiovascular intervention management expert group of the National Health Commission:

Especially in China, the treatment of acute myocardial infarction is seriously insufficient, because coronary intervention for acute myocardial infarction, which means that stent placement, is the most effective way to reduce patients A means of death.

Probably only accounts for less than 10% of patients with acute myocardial infarction.

Especially these patients, a considerable number of patients, have not been able to receive such treatment in time.

Therefore, the future development of interventional treatment of coronary heart disease in China is still great.